Rapport Therapeutics (RAPP) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tyra Biosciences (TYRA) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 46.5% versus a gain of 10.3%. Rapport Therapeutics is the larger company by market cap ($1.43 billion vs $1.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RAPP | TYRA |
|---|---|---|
| Share price | $29.85 | $19.97 |
| Market cap | $1.43B | $1.37B |
| 1-day change | -3.27% | -2.06% |
| YTD return | -1.62% | -24.04% |
| 1-year return | +10.31% | +46.52% |
| 5-year return | — | +22.22% |
| EPS (TTM) | $-3.03 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.93 | $40.65 |
| 52-week low | $23.75 | $13.29 |
| Distance from 52-week high | -43.60% | -50.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.19% | +137.61% |
| Average volume | 359.60K | 857.13K |
| Shares outstanding | 47.98M | 68.76M |
| Employees | 84 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TYRA has outperformed RAPP by 36.2 percentage points over the past year.
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
RAPP vs TYRA FAQ
Which is bigger, Rapport Therapeutics or Tyra Biosciences?
Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.43B compared with $1.37B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, RAPP or TYRA?
TYRA returned +46.52% over the past 12 months, compared with +10.31% for RAPP (price return, excluding dividends). Past performance does not predict future results.
Are Rapport Therapeutics and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.